Replimune REPL Stock
Replimune Price Chart
Replimune REPL Financial and Trading Overview
| Replimune stock price | 7.14 USD |
| Previous Close | 23.48 USD |
| Open | 24.6 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 23.92 - 24.81 USD |
| 52 Week Range | 14.21 - 29.52 USD |
| Volume | 638.66K USD |
| Avg. Volume | 612.07K USD |
| Market Cap | 1.39B USD |
| Beta (5Y Monthly) | 1.644102 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.11 USD |
REPL Valuation Measures
| Enterprise Value | 833.95M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.2227983 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.4515207 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.856 |
Trading Information
Replimune Stock Price History
| Beta (5Y Monthly) | 1.644102 |
| 52-Week Change | 58.02% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 29.52 USD |
| 52 Week Low | 14.21 USD |
| 50-Day Moving Average | 18.84 USD |
| 200-Day Moving Average | 20.81 USD |
REPL Share Statistics
| Avg. Volume (3 month) | 612.07K USD |
| Avg. Daily Volume (10-Days) | 841.27K USD |
| Shares Outstanding | 57.78M |
| Float | 42.31M |
| Short Ratio | 15.66 |
| % Held by Insiders | 8.47% |
| % Held by Institutions | 87.32% |
| Shares Short | 7.32M |
| Short % of Float | 17.07% |
| Short % of Shares Outstanding | 12.66% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.65% |
| Return on Equity (ttm) | -36.064% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -171719008 USD |
| Net Income Avi to Common (ttm) | -174284000 USD |
| Diluted EPS (ttm) | -2.99 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 583.39M USD |
| Total Cash Per Share (mrq) | 10.1 USD |
| Total Debt (mrq) | 60.76M USD |
| Total Debt/Equity (mrq) | 10.94 USD |
| Current Ratio (mrq) | 17.52 |
| Book Value Per Share (mrq) | 9.798 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -128050000 USD |
| Levered Free Cash Flow (ttm) | -71096752 USD |
Profile of Replimune
| Country | United States |
| State | MA |
| City | Woburn |
| Address | 500 Unicorn Park Drive |
| ZIP | 01801 |
| Phone | 781 222 9600 |
| Website | https://www.replimune.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 284 |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Q&A For Replimune Stock
What is a current REPL stock price?
Replimune REPL stock price today per share is 7.14 USD.
How to purchase Replimune stock?
You can buy REPL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Replimune?
The stock symbol or ticker of Replimune is REPL.
Which industry does the Replimune company belong to?
The Replimune industry is Biotechnology.
How many shares does Replimune have in circulation?
The max supply of Replimune shares is 61.39M.
What is Replimune Price to Earnings Ratio (PE Ratio)?
Replimune PE Ratio is now.
What was Replimune earnings per share over the trailing 12 months (TTM)?
Replimune EPS is -3.16 USD over the trailing 12 months.
Which sector does the Replimune company belong to?
The Replimune sector is Healthcare.
Replimune REPL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2060.1 USD — |
-1.99
|
— — | 2051.95 USD — | 2093.4 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}